{‘She possesses zero qualifications’: this American scientific establishment braces for Dr. Høeg's role at the Food and Drug Administration.

Given that America undertakes unprecedented revisions to its vaccine guidelines, an unexpected name appears in a surprising turn: Tracy Beth Høeg, a US-based sports physician and epidemiologist who rose to prominence by expressing skepticism about COVID-19 shots throughout the global health crisis and has zeroed in on alleged fatalities following COVID-19 vaccination in her brief position at the Food and Drug Administration.

Scheduled Overhauls to Childhood Immunization Program

Agency leaders were set to reveal major changes to the pediatric immunization program recently, bringing the US with the Danish immunization schedule, sources say – a substantial departure that would place the US at odds with a large portion of the international standard with little proof for improved outcomes. The planned update has been postponed until the new year.

Rather than the director of the vaccine center, Høeg is scheduled to address the audience at the gathering. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth person to run the office this year.

A Shift at the Agency

Høeg's temporary position could signify a strengthened alliance between the pharmaceutical and vaccine branches as Høeg and Prasad solidify control at the agency – and it suggests a renewed priority upon dismantling previously authorized immunizations at the FDA.

Høeg has often pushed for discontinuing some childhood shot schedules in the US in order to be more in line with Denmark's approach, a country with universal health coverage and a citizenry roughly the size of Wisconsin’s.

So far statements, she has kept her attention on immunizations – usually the responsibility of Prasad, head of the FDA’s CBER – instead of medication approval.

Questions Over Background

The appointee has no obvious track record in pharmaceutical research, regulation or leadership, which has been standard for former heads of the Center for Biologics Evaluation and Research. She has worked at the FDA as a senior adviser to the commissioner and CBER since earlier this year.

“It seems she lacks to have any of the qualifications” for running the CDER, said Dr. Jonathan Howard. “She has not conducted a scientific study. She lacks experience in leading a large organization. She is not an expert in pharmaceutical oversight.”

Former commissioners of the center would “understand legal statutes and the science of drug development”, commented a former acting FDA commissioner. “Clearly, she has not acquired the type of experience that prior appointees who ran CBER have had.”

This division has an vast range of responsibilities at the agency, Woodcock pointed out.

“The public just pays attention on the novel medication approvals, but the generic drug division clears thousands of off-brand pharmaceuticals. There is also a biologic copycat branch, OTC medication office and so forth, and each of these must be supervised,” Woodcock said. “The thing you overlook, that is the part that I always told people is going to come back to haunt you.”

Additionally, a significant management aspect to the job, which oversees in excess of 5,000 personnel. “It’s a massive administrative position, if you do it right,” she said.

Agency Reaction and Disputed Programs

When asked about questions about Høeg’s qualifications and whether this selection indicates more teamwork among regulatory chiefs on immunizations, a representative said that the “inquiries are based on flawed premises”.

“Her resume matches the duties of her job,” the representative explained, noting the time Høeg spent counseling the FDA commissioner on “drug safety and oversight research, including computational safety modeling and vaccine surveillance”.

As acting director, Høeg takes over the agency head's recently launched expedited review system, a contentious expedited therapy clearance system that apparently worried her former heads. “How are these medications being picked for this fast-track system? Who makes the decisions?” Howard asked. “There is a lot of lack of transparency happening at the regulatory body right now.”

Overall, he remarked, “the FDA seems to be moving towards less stringent rules of all drugs, except for shots.”

Established History on Vaccines

With vaccines, Høeg has a more established, if concerning, track record, critics have noted. She published a analysis using unconfirmed crowd-sourced reports to estimate the rate of myocarditis after Covid immunization. She advised the state of Florida chief medical officer Joseph Ladapo, who was said to have changed statistics to suggest COVID-19 vaccinations are more dangerous than they are.

Included in her “desired changes” for the incoming government featured revising rules for recently developed shots and halting “unnecessary” immunizations, she stated post-election on a audio program. At the FDA, Høeg has allegedly suggested barring young men from obtaining COVID-19 vaccines.

“She’s an all-around dogmatist who begins with her conclusions and reverse-engineers to retrofit the science in a very disingenuous, untruthful fashion,” Dr. Howard stated.

Gaining Influence and a “Revenge Tour”

Dr. Høeg aligned with other dissenters, {like|